Literature DB >> 33630159

A 2-year investigation of the impact of the computed tomography-derived fractional flow reserve calculated using a deep learning algorithm on routine decision-making for coronary artery disease management.

Xin Liu1, Xukai Mo2,3, Heye Zhang4, Guang Yang5, Changzheng Shi6,7, William Kongtou Hau8.   

Abstract

OBJECTIVE: This study aims to investigate the safety and feasibility of using a deep learning algorithm to calculate computed tomography angiography-based fractional flow reserve (DL-FFRCT) as an alternative to invasive coronary angiography (ICA) in the selection of patients for coronary intervention.
MATERIALS AND METHODS: Patients (N = 296) with symptomatic coronary artery disease identified by coronary computed tomography angiography (CTA) with stenosis over 50% were retrospectively enrolled from a single centre in this study. ICA-guided interventions were performed in patients at admission, and DL-FFRCT was conducted retrospectively. The influences on decision-making by using DL-FFRCT and the clinical outcome were compared to those of ICA-guided care for symptomatic CAD at the 2-year follow-up evaluation. RESULT: Two hundred forty-three patients were evaluated. Up to 72% of diagnostic ICA studies could have been avoided by using a DL-FFRCT value > 0.8 as a cut-off for intervention. A similar major adverse cardiovascular event (MACE) rate was observed in patients who underwent revascularisation with a DL-FFRCT value ≤ 0.8 (2.9%) compared to that of ICA-guided interventions (3.3%) (stented lesions with ICA stenosis > 75%) (p = 0.838).
CONCLUSION: DL-FFRCT can reduce the need for diagnostic coronary angiography when identifying patients suitable for coronary intervention. A low MACE rate was found in a 2-year follow-up investigation. KEY POINTS: • Seventy-two percent of diagnostic ICA studies could have been avoided by using a DL-FFRCT value > 0.8 as a cut-off for intervention. • Coronary artery stenting based on the diagnosis by using a 320-detector row CT scanner and a positive DL-FFRCT value could potentially be associated with a lower occurrence rate of major adverse cardiovascular events (2.9%) within the first 2 years. • A low event rate was found when intervention was performed in tandem lesions with haemodynamic significance based on DL-FFRCT < 0.8 as a cut-off value.
© 2021. European Society of Radiology.

Entities:  

Keywords:  Computed tomography angiography; Coronary artery disease; Deep learning; Myocardial fractional flow reserve; Myocardial revascularisation

Mesh:

Year:  2021        PMID: 33630159     DOI: 10.1007/s00330-021-07771-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  5 in total

1.  Effect of 320-row CT reconstruction technology on fractional flow reserve derived from coronary CT angiography based on machine learning: single- versus multiple-cardiac periodic images.

Authors:  Ke Shi; Feng-Feng Yang; Nuo Si; Chen-Tao Zhu; Na Li; Xiao-Lin Dong; Yan Guo; Tong Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-06

2.  Artificial Algorithms Outperform Traditional Models in Predicting Coronary Artery Disease.

Authors:  Lutfu Askin; Okan Tanrıverdi; Mustafa Cetin
Journal:  Arq Bras Cardiol       Date:  2021-12       Impact factor: 2.667

Review 3.  Current and Future Applications of Artificial Intelligence in Coronary Artery Disease.

Authors:  Nitesh Gautam; Prachi Saluja; Abdallah Malkawi; Mark G Rabbat; Mouaz H Al-Mallah; Gianluca Pontone; Yiye Zhang; Benjamin C Lee; Subhi J Al'Aref
Journal:  Healthcare (Basel)       Date:  2022-01-26

4.  Case Report: Dual-Energy Computed Tomography of Cardiac Changes in IgG4-Related Disease.

Authors:  Ying Wang; Hui Zhou; Ping Hu; Jie Zhao; Yitao Mao; Zhixiao Li; Xi Zhao
Journal:  Front Cardiovasc Med       Date:  2022-03-04

Review 5.  Artificial Intelligence-A Good Assistant to Multi-Modality Imaging in Managing Acute Coronary Syndrome.

Authors:  Ming-Hao Liu; Chen Zhao; Shengfang Wang; Haibo Jia; Bo Yu
Journal:  Front Cardiovasc Med       Date:  2022-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.